Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability

Barough, Mahdieh Shokrollahi; Ashtari, Fereshteh; Akhavi, Mehdi Sadat; Asghari, Nabiollah; Mosayebi, Ghasem; Mirmohammadkhani, Majid; Kokhaei, Naser; Bahraminia, Farhad; Ajami, Arman; Kokhaei, Parviz

doi:10.1016/j.intimp.2018.06.032

Cited by 4 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 In a study conducted by Shokrollahi et al, the recipients of ReciGen and Rebif were studied for the amount of NAbs, and as a result, it was found that there was no significant difference between the consumers of these two drugs in terms of neutralizing antibody positivity. 13 Unfortunately, despite the high consumption of this drug in Iran, few studies have evaluated the effect of ReciGen on MS patients. In 2020, following the use of interferons in the treatment of COVID-19, three studies examined the effectiveness of ReciGen in the treatment of COVID-19 indicating that the use of ReciGen could significantly reduce the severity of COVID-19.…”

Section: Recigenmentioning

confidence: 99%

Biosimilars in Treatment of Multiple Sclerosis in Iran

Moghadasi

2021

Arch Iran Med

View full text Add to dashboard Cite

Biological drugs are manufactured via some changes made to the living organisms by genetic engineering. Notably, biological drugs are very expensive and their importation can impose economic pressure, especially on poorer countries. Thereafter, manufacturing these drugs has been considered by policymakers in many countries, resulting in the production of biosimilars. Iran requires a wide range of biological drugs due to the growing number of patients with multiple sclerosis. On the other hand, the poor economic situation of Iran due to repeated sanctions has had a great impact on the health care system, which has prevented the allocation of sufficient financial resources in this regard. Therefore, manufacturing biosimilar drugs due to their lower cost has received much attention in various fields of treatment.

show abstract

Section: Recigenmentioning

confidence: 99%

Biosimilars in Treatment of Multiple Sclerosis in Iran

Moghadasi

2021

Arch Iran Med

View full text Add to dashboard Cite

show abstract

“…Ever since the introduction of insulin as the first therapeutic protein, it has been an ever-expanding field. 1 Biotherapeutics are used to treat a broad range of severe diseases, for instance the immune messenger cytokines interferon beta (IFNβ) and alpha (IFNα) products are used to treat multiple sclerosis (MS) 2 and viral diseases 3 respectively. Moreover monoclonal antibodies are used to treat a range of diseases: autoimmune diseases – such as MS 4 and Guillain-Barré syndrome 5 – chronic inflammatory diseases, such as Crohn's disease, 6 as well as numerous cancers.…”

Section: Introductionmentioning

confidence: 99%

“…Development of neutralizing antibodies against IFNβ in relapse-remitting multiple sclerosis (RRMS) patients has been shown to inhibit IFNβ induced signalling 23 and leads to an irreversible increase in disease score. 2 Furthermore, anemic patients with chronic renal failure that were positive for neutralizing antibodies against recombinant human erythropoietin developed pure red cell aplasia (an absence of red blood cell precursors). 24 Regarding the role of protein aggregation, in two cases of neutralizing antibodies reported during a pre-marketing clinical trial for recombinant erythropoietin, this immune response was proposed to be due to a high degree of aggregation.…”

Section: Introductionmentioning

confidence: 99%